← All trials
NCT03630705
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2018
- Primary completion
- May 31, 2020
- Completion date
- May 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 825
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sanofi-AventisLead sponsor
- Sanofi-AventisStudy director
Drugs studied
- meningococcal (groups A, C, Y, W) CRM197 conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- hepatitis b vaccine (recombinant)
- rotavirus vaccine, live, oral, pentavalent
- measles, mumps, and rubella vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- quadrivalent groups a, c, y, and w-135 meningococcal vaccine
- tetanus toxoid
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.